Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions
Authors:
- Monica FalleniMFMonica Falleni
- Caterina PellegriniCPCaterina Pellegrini
- Antonio MarchettiAMAntonio Marchetti
- Massimo RoncalliMRMassimo Roncalli
- Mario NosottiMNMario Nosotti
- Alessandro PalleschiAPAlessandro Palleschi
- Luigi SantambrogioLSLuigi Santambrogio
- Guido CoggiGCGuido Coggi
- Silvano BosariSBSilvano Bosari
- 31 May 2005
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 48 (2) , 211-216
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Survivin gene expression in early‐stage non‐small cell lung cancerThe Journal of Pathology, 2003
- Validating survivin as a cancer therapeutic targetNature Reviews Cancer, 2003
- A Role for Survivin in Radioresistance of Pancreatic Cancer CellsJapanese Journal of Cancer Research, 2002
- Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesotheliomaCancer Gene Therapy, 2001
- Mechanisms of ApoptosisThe American Journal of Pathology, 2000
- Survivin as a Radioresistance Factor in Pancreatic CancerJapanese Journal of Cancer Research, 2000
- Pleural mesotheliomaCurrent Opinion in Pulmonary Medicine, 1999
- bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancerInternational Journal of Cancer, 1996
- Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesotheliumVirchows Archiv, 1994
- Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell deathCell, 1993